Barclays analyst Lukas Shumway downgraded Cellectis (NASDAQ: CLLS) from Overweight to Underweight with a price target of $1.30 (from $9.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE